Michelle Teng
CEO
Etcembly
Etcembly utilizes AI-driven protein language models to design and optimize T-cell receptors (TCRs) and antibodies, significantly enhancing the precision and safety of immunotherapy candidates for cancer treatment. The startup addresses the urgent need for faster drug discovery by leveraging extensive immune repertoire databases and advanced sequencing technologies to identify novel therapeutic targets.
- Artificial Intelligence
- Biotechnology
Updated 7 months ago
Funding
Funding not disclosed
Funding rounds are not available yet.
Founders
Jacob Hurst
CTO
Product
Problem
The development of effective immunotherapies for cancer is hindered by the challenges of designing and optimizing T-cell receptors (TCRs) and antibodies with the required precision, safety, and speed. Traditional drug discovery methods struggle to efficiently identify and validate novel therapeutic targets from vast immune repertoire data.
Solution
Etcembly offers an AI-driven platform, EMLy™, that accelerates the design and optimization of TCRs and antibodies for cancer immunotherapy. By leveraging protein language models and extensive immune repertoire databases, EMLy™ identifies novel therapeutic targets and enhances the precision and safety of drug candidates. The platform supports the rapid engineering of new candidates and biobetters, including TCRs, antibodies, bispecifics, and VHHs. Etcembly's Long-term Cancer Survivor Study further enhances target discovery by investigating the immune repertoires of patients cured by immunotherapies.
Target Audience
Etcembly's primary customers are biotechnology and pharmaceutical companies involved in cancer immunotherapy drug discovery and development.
Features
- EMLy™: A multi-modality platform with protein language models designed for TCR, antibody, and bispecific design.
- AI-driven affinity optimization to predict affinity-matured variants of TCR/antibody sequences.
- Stability and developability enhancement to supercharge the expression yield of assets.
- Deep sequencing capabilities to access and analyze immune repertoires with databases of 1 billion TCRs and 2 billion antibodies.
- Co-pilot feature that empowers scientists with informatics and insights.
- Long-term Cancer Survivor Study to uncover novel TCRs, antibodies, and targets.